Hadasit Bio-Holdings Ltd (HSITF)
Hadasit Bio-Holdings Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Jerusalem, IL. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $1.3M. On trailing twelve-month figures it carries a trailing P/E of -4.47, a net margin of 0.0%. Its beta of 0.49 implies it has historically moved less than the broad market.
Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases. A key offering is ProtAb, an immunotherapeutic monoclonal antibody engineered to treat autoimmune inflammatory disorders.
Hadasit Bio-Holdings Ltd is most often compared with the following Healthcare names: